SPRO Dividend History & Description — Spero Therapeutics Inc
Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting. When considering the Spero Therapeutics Inc stock dividend history, we have taken known splits into account, such that the SPRO dividend history is presented on a split-adjusted ("apples to apples") basis. Spero Therapeutics Inc dividend history is presented both in graphical/chart form, and as a SPRO dividend history data table along the right-hand column.